Home » Stocks » MLND

Millendo Therapeutics, Inc. (MLND)

Stock Price: $1.01 USD -0.03 (-2.88%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $1.03 +0.02 (1.98%) May 12, 6:52 PM
Market Cap 20.57M
Revenue (ttm) n/a
Net Income (ttm) -36.41M
Shares Out 18.86M
EPS (ttm) -1.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $1.01
Previous Close $1.04
Change ($) -0.03
Change (%) -2.88%
Day's Open 1.02
Day's Range 1.00 - 1.07
Day's Volume 756,541
52-Week Range 0.92 - 3.64

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, April 27, 2021 /PRNewswire/ -- If you own Millendo shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: ht...

2 weeks ago - PRNewsWire

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therape...

1 month ago - Business Wire

NEW YORK, April 2, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...

1 month ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair t...

1 month ago - Business Wire

Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics mo...

1 month ago - Benzinga

SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics and Tempest Therapeutics announce a proposed merger agreement.

1 month ago - Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces updates on its pipeline and business, including its Phase 1 study of MLE-301 for the treatment of vasomotor symptoms.

4 months ago - Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces operating and financial results for the quarter ended September 30, 2020.

6 months ago - Business Wire

There are some investors who buy stocks that are trading below their liquidation value because they believe they can achieve impressive gains from their investments after the market has reassessed the s...

Other stocks mentioned: CGA, UTSI
6 months ago - GuruFocus

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with sig...

7 months ago - Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Participate in September Investor Conferences

8 months ago - Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

9 months ago - Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

9 months ago - Business Wire

Investors need to pay close attention to Millendo (MLND) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Millendo Therapeutics.

1 year ago - Zacks Investment Research

Millendo Therapeutics: A Forgotten Biotech With Strong Potential

1 year ago - Seeking Alpha

Millendo Therapeutics Inc’s (NASDAQ: MLND) lead asset livoletide is in a registrational study (ZEPHYR) for the treatment of PraderWilli Syndrome (PWS), which is an unmet need, according to Wedbush.

1 year ago - Benzinga

It’s not that unusual in the world of biotech and emerging medtech to run across companies that have previously never been heard of or covered.

1 year ago - 24/7 Wall Street

About MLND

Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

Industry
Biotechnology
CEO
Julia Owens
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
MLND
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for MLND stock is "Hold." The 12-month stock price forecast is 2.00, which is an increase of 98.02% from the latest price.

Price Target
$2.00
(98.02% upside)
Analyst Consensus: Hold